Index

505(b)(2) application, 258
510(k) submission, 269, 276
typical content, 277
Abbott, 348
Abbreviated New Drug Application (ANDA), 256
accelerated approval process, 263
active pharmaceutical ingredient (API), 195
Active Pharmaceutical Ingredient (API), 325
Advanced Tissue Sciences (ATS), 299
Ambulatory Payment Classifications (APC), 389
American Society for Testing of Materials (ASTM), 323
Amgen, 327, 386
analyte specific reagents (ASRs), 204, 287
angel investor, 109
art of persuasion, 229, 236
artificial intelligence/machine learning (AI/ML), 292
Aspect Medical Systems, 411
Baxter, 379
Bayh–Dole Act, 161
bioinformatics, 12
biologics
production technology, 27
biomarker, 290
biomedical technology
definition, 3
biopharmaceutical industry, 7
biosimilars, 257
biotechnology
agricultural applications, 6
applications, 5
definition, 5
industrial applications, 5
biotechnology
environmental applications, 5
breakthrough innovation, 177
business model, xvii, 88
cash-flow positive, 92
changing, 90
horizontal platform, 94
hybrid horizontal and vertical, 95
quantitative, 91
services to products, 95
single-product company, 107
vertical, 93
virtual company, 95
business plan, 84
assumptions and risks, 87
components, 84–85
CAR T-Cell gene therapy, 303
CBER
Office of Cellular, Tissue and Gene Therapies, 241
CE mark, 271
CE Technical Documentation, 277
Center for Biologics Evaluation and Research (CBER), 241
Center for Devices and Radiological Health (CDRH), 242
Center for Drug Evaluation and Research (CDER), 242
Centers for Medicare & Medicaid Services (CMS), 285, 366
Chakrabarty, Ananda, 126
Clinical Laboratory Improvement Amendments (CLIA), 281, 285
clinical study
design for device product, 216
design for drug product, 196
for in vitro diagnostic (IVD) devices, 207
patient selection, 197
Phase I – safety, 198
Phase II – efficacy, 199
Phase III – registration trial, 201
phase IV – post marketing, 201
randomized, 199
real-world data, 184
simple and composite endpoints, 184
trial endpoints for regulatory vs payers, 174
Code of Federal regulations (CFR), 234, 240
combination product, 291
combination products
examples, 3
regulatory process pathways, 298
tissue engineered products, 298
commercial manufacturing plan
for drug products, 333
commercialization plan, xvii, 86
components, xix
companion diagnostic, 207
regulatory process pathways, 289
company formation
board composition, 81
common mistake, 81
leadership roles, 83
management roles, 83
Contract manufacturing organization (CMO) 349
Corrective and Preventive Actions (CAPA), 320
cost effectiveness considerations by payers
Germany’s Institute for Quality and Efficiency in Healthcare, 378
Japan, 378
quality-adjusted life years (QALYs), 378
Taiwan, 379
critical path method (CPM), 222
current good manufacturing practices (cGMP). See Good manufacturing practices (GMP)
Current Procedural Terminology codes (CPT codes), 383
dermagraft, 301
design history file (DHF), 273
device master record (DMR), 273, 321
device product development
clinical trial stages, 219
Design for Six Sigma, 213
design inputs, 211
development team composition, 224
do’s and don’ts, 219
human factors engineering, 214
product design specifications (PDS), 211
production prototype, 215
Quality Function Deployment (QFD), 211
regulatory process pathways, 267
diagnostics, 9
business model, 93
IVD market size, 10
lab-on-a-chip, 31
molecular, 10
next generation sequencing, 31
point-of-care, 26
product types, 9
sequencing, 12
diagnostics product development
assay optimization, 205
discovery and validation, 202
regulatory process and pathways, 281
regulatory process pathways, 267, 283
distribution
drug formulary, 371
drug product, 369
medical devices, 372
drug
definition, 4
DRG (Diagnosis Related Group) codes 383, 389, 398, 401, 405
IPPS, 398
Drug Master File (DMF), 256
drug product development
biological drug, 195
chemical and manufacturing controls (CMC), 252
cost estimate, 17
excipients, 195
hit to lead optimization, 192
process value chain, 17
regulatory process, 249
scale-up requirements, 332
stage-gate criteria, 202
target discovery, 191
target validation, 192
toxicity testing, 194
emerging technologies
integration in biotech and devices, 35
therapeutics, 30
etanercept (Enbrel), 399
EU Medical Device Regulation (MDR), 271–272
notified body, 290
European Medicine Agency (EMA)
quality management system QMS, 275
European Medicines Agency (EMA), 257
Fast Track Drug Development Program, 259
FDA
accelerated approval process for drug products, 263
drug regulatory pathway, 250
formal meetings for device developers, 271
gatekeeper to the market, 241
general controls, 272
guidance documents, 244, 273
interactions, 254
meetings, 254
Office of Combination Products (OCP), 291
Office of Orphan Products, 265
priority review for drug product, 264
special controls, 273
surveillance program, 258
financial plan, 87
cash-flow positive, 92
milestone-based, 105
Food and Drug Administration (FDA), xvii, 239
Formulary, 371, 422
founder
equity split, 97–98
market perceiver, 79
founders
diversity, 79
team, 78
values, 78
Gantt chart, 222
gene therapy
CRISPR, 7
genomic health, 406
Glaxo SmithKline, 414
good clinical practice (cGCP), 196
good laboratory practice (cGLP), 195
good machine learning principles (GMLP), 293
good manufacturing practices (GMP), 195, 316
documentation, 321
process controls, 332
process validation, 317
quality assurance (QA)/quality control (QC), 316
standards, 322
gross domestic product (GDP), 364
Hatch–Waxman Amendments, 265
health insurance
cost effectiveness, 377
employer USA, 365
private insurers, 367
reimbursement, 369
health maintenance organization (HMO), 368
healthcare economics. See cost effectiveness
considerations by payers
healthcare marketplace, 2
healthcare systems
Australia, 410
Canada, 409
China, 410
France, 409
Germany, 410
India, 410
House of Quality. See device product development:
Quality Function Deployment
humanitarian use device (HUD), 279
ICD-10/11 diagnosis codes, 387
IMDRF
harmonization in medical device regulations, 293
in vitro diagnostics (IVD). See diagnostics
Inamed, 302
India drug patent rights, 128
indication, 70
FDA label, 183, 241
input into new product development, 167
Inflammatix, 345, 407
infliximab (Remicade), 399
informed consent, 182
form, 182
Institute for Clinical and Economic Review (ICER), 378
Institutional Animal Care and Use Committee (IACUC), 180
Institutional Review Board (IRB), 181, 253
intellectual property (IP)
management strategy, 159
market value, 123
value, 155
Intergenetics, 282
International Conference for Harmonization (ICH), 244
International Organization for Standardization (ISO), 323
International Patent Classification – IPC, 134
International Standardization Organization (ISO), 164
International Standards Organization (ISO), 316
Investigational Device Exemption (IDE), 270
Investigational New Drug Application (IND), 195, 252
ISO 13485, 325
ISO 9001, 325
J&J, 326
Label 183, 241, 258, 289
IVD 344
Claims 216
Package insert, 255
Generic, 257
Off-label use 377
laboratory developed test (LDT), 284, 288
licensing
exclusive, non-exclusive, or sole, 152
key terms in agreement, 151
local coverage decision (LCD), 376
lot qualification, 312
manufacturing
biological drugs, 326
buy or build decision, 349
culture, 328
management tips, 330
packaging, 342
small molecule drugs, 326
sterilization, 343
sterilization process, 362
market
hypothesis testing, 48
indication, 69
pain point, 48
penetration, 58
Survey, 52
target segment, 48
who is the customer, 69, 85
market adoption, 411
market size, 44
market validation, 43
marketing
Key opinion leaders, 412
Medicaid, 367
medical device classification, 268
Index

medical device (cont.)
definition, 8, 209, 267
FDA classification, 209
Four ‘P’s of marketing strategy, 411
market size, 8
smart, 12
Medical Device User Fee and Modernization Act (MDUFMA), 244
medical devices
emerging technologies, 31
Medical Science Liaison (MSL), 414
Medicare, 366
Medicare Administrative Contractor (MAC), 376
Medicare Coverage of Innovative Technology (MCIT), 392
Medtronic, 400
Minimum Viable Product (MVP), 169
Mitchell Sugarman, 400
Mobile computing
impact on product development, 32
molecular diagnostic tests, 286
Monoclonal antibody, 6
MSDS (Materials Safety Data Sheets), 235
Myriad Genetics Inc, 127
NAICS codes, 39
Nassib Chamoun, 413
National Coverage Decision (NCD), 376
net present value (NPV), 230
new chemical entities (NCEs), 264
New Drug Application (NDA), 254
new product development (NPD), See product development
New Technology Add-On Payment (NTAP), 392
Novartis, 303
nucleic acid tests (NATs), 286
nucleic acid therapies, 26
Orange Book, 265
organogenesis, 301
Orphan Drug Act, 265
Outpatient Payment System (OPPS), 389
over-the-counter (OTC) drug products, 258
Pasteur, Louis, 126
patent
claims, 135
composition of matter, 124
contents, 124
Continuation in part (CIP), 145
costs, 130
first-to-file, 137
freedom to operate (FTO), 132, 143
infringement, 142
invention conceptualization, 132
licensing, 149
monetization, 148
prior art, 133–134
priority date, 137, 141
process patent, 124
Provisional application, 145
reduction to practice, 132
stem cells, 127
term extension by FDA, 265
utility patent types, 124
value, 155
what cannot be patented, 125
who is an inventor, 133
Patent Cooperation Treaty (PCT), 139
procedure and timeline, 140
payments
flow
devices diagnostics reimbursement, 372
devices, diagnostics, physician-administered
drugs, 387
drug product sale and reimbursement, 370
infused drugs reimbursement, 372
reimbursement, 374
self-administered drugs, 395
personalized medicine, 34
Pfizer, 379, 414
pharmaceutical industry
R&D investment, 30
pharmacoeconomics. See cost effectiveness
considerations by payers
pharmacogenomics, 288
pharmacokinetic (PK), 251
pharmacy benefit manager (PBM), 370
Physician’s Fee Schedule, 408
Popovits, Kim, 406
Porter’s Five Forces, 13, 18, 21–22
predicate 510(k) devices, 269
preferred provider organizations (PPO), 368
Pre-Market Approval (PMA), 269
content, 278
types, 279
Prescription Drug User Fee Act (PDUFA), 243
Priority Review, 264
private placement memorandum (PPM), 97, 111
product development
adapting to uncertainty, 176
addressing key risk factors, 168
breakthrough projects, 177
discovery-driven planning, 177
fail fast, fail early, 173
first customer, 105
Gantt chart, 222
milestones as risk reduction, 168
multidisciplinary inputs, 164
outsourcing considerations, 231
product life cycle planning, 166
Index

regulatory requirements, 180
stage-gate process, 178
statistical analysis, 184
typical failure points devices, 172
typical failure points diagnostics, 170
typical failure points drugs, 170
vs academic science, 101
product liability lawsuits, 415
project management, 225
budget planning, 225
matrix organization, 225
Net Present Value (NPV), 229
stakeholder analysis, 230
Propeller Health Inc, 297
prototype
in market research, 50
Quality System Regulation, 211
corrective and preventive action (CAPA), 359
design controls, 211, 273, 359
management controls, 358
medical device reporting regulations (MDR), 360
QSR rules for devices, 318
Quality System Regulation (QSR), 273
major subsystems, 320
rereferral chain, 50
definition, 60
key value proposition, 63
Regenerative Medicine Advanced Therapies (RMAT), 298
Regeneron Pharmaceuticals Inc, 311, 328, 335
reimbursement
ASP (average sales price) for drugs, 385
AWP (average wholesale price) for drugs, 385
calculating physicians’ payment, 389
codes for payment systems, 383
components, 374
coverage, 374
coverage decision by data from clinical study, 382
diagnostics, 404
diagnostics cross-walk and gap fill calculations, 404
diagnostics payment calculation, 390
erly planning for drug products, 395
Medicare Coverage of Innovative Technology (MCIT), 375
payment levels decision, 385
planning strategy early stage, 393
prospective payments, 389
technology assessment review, 380
Romanowsky, Jonathan, 347, 407
royalty rate
anti-stacking royalty, 157
rule of thumb, 156
scientist-founders, xix
Slurzberg, Jo Ellen, 403
Small Business Innovation Research (SBIR) grants, 113
small molecule drugs, 4
Smith and Nephew, 302
software
in devices, 12
software as a medical device (SaMD), 292
good machine learning principles (GMLP), 293
MDR classification, 293
prescription video game example, 296
regulatory classification, 294
standard operating procedures (SOPs), 273
standards, 322
startup
advisory board, 83
CEO role in team building, 104
culture, 78, 104
due diligence in financing, 111–112
equity vesting, 97
incubator, 101
managing conflict resolution, 115
managing technical genius bad actors, 117
strategic financing, 114
typical investment term sheet, 110
valuation, 108
venture debt financing, 114
Sulzer Orthopedics, 344
supply chain, 13
target product profile (TPP), 43
example for drug, 188
strategic document, 184
technical founder
technopreneur, 45, 79
technical founders as business leader, 44
self-awareness, 44
technology transfer
as a contact sport, 149
R&D to manufacturing, 309
typical failure points, 310
trade secret, 123, 148
trademarks, 145
United States Code (U.S.C.), 240
U.S. Patent and Trademark Office (US PTO), 128
value chain
definition, 13
in business model, 14
VanPlew, Dan, 311, 335
venture capital, 108
voice of customer
input to product development, 167
Voluntis, 297
Warranty 415
WellDoc, 296
World Health Organization (WHO), 384
World Intellectual Property Organization (WIPO), 139